Objective To investigate the effect of bevacizumab combined with carboplatin and docetaxel on the serum related factors and prognosis of recurrent ovarian cancer.Methods A total of 32 patients with recurrent ovarian cancer admitted from 2022.1.1 to 2023.6.30 were selected as the study subjects,and they were divided into the study group(n=16)and the control group(n=16)by simple random grouping method.The control group was treated with carboplatin and docetaxel,and the study group was treated with a combination of bevacizumab,carboplatin and docetaxel.The tumor markers[carbohydrate antigen 125(CA125),human epididymal protein 4(HE4)]and vascular endothelial growth factor(VEGF)before and after 6 courses of treatment were compared between the two groups,and the adverse reactions and short-term efficacy of the two groups were compared.Results After treatment,the CA125 and HE4 levels in the two groups decreased compared with those before treatment(P＜0.05).After treatment,the CA125 and HE4 levels in the study group were lower than those in the control group(P＜0.05).After treatment,the VEGF in the two groups decreased compared with that before treatment(P＜0.05),and after treatment,the VEGF in the study group was lower than that in the control group(P＜0.05).The total incidence of adverse reactions in the study group was 62.50%compared with that in the control group(50.00%)after 6 courses of treatment,and the difference was not statistically significant(P＞0.05).After 6 courses of treatment,the RR and DCR of the study group were significantly higher than those of the control group(P＜0.05).Conclusion Bevacizumab combined with carbo-platin and docetaxel in the treatment of recurrent ovarian cancer can improve the levels of tumor markers and vascular growth factor,and improve the anti-tumor effect,with significant efficacy and high safety.
NETL
NSTL
万方数据
